Rethinking ovarian cancer: recommendations for improving outcomes

被引：1009

作者：

Vaughan, Sebastian ^{[3
]}

Coward, Jermaine I. ^{[4
]}

Bast, Robert C., Jr. ^{[5
]}

Berchuck, Andy ^{[6
]}

Berek, Jonathan S. ^{[7
]}

Brenton, James D. ^{[8
]}

Coukos, George ^{[24
]}

Crum, Christopher C. ^{[25
]}

Drapkin, Ronny ^{[23
]}

Etemadmoghadam, Dariush ^{[22
]}

Friedlander, Michael ^{[21
]}

Gabra, Hani ^{[3
]}

Kaye, Stan B. ^{[20
]}

Lord, Chris J. ^{[19
]}

Lengyel, Ernst ^{[18
]}

Levine, Douglas A. ^{[17
]}

McNeish, Iain A. ^{[16
]}

Menon, Usha ^{[15
]}

Mills, Gordon B.

Nephew, Kenneth P. ^{[14
]}

Oza, Amit M. ^{[13
]}

Sood, Anil K. ^{[11
,12
]}

Stronach, Euan A. ^{[3
]}

Walczak, Henning ^{[10
]}

Bowtell, David D. ^{[1
,2
]}

Balkwill, Frances R. ^{[9
]}

机构：

[1] Univ Melbourne, Canc Genom & Genet Program, Melbourne, Vic 8006, Australia

[2] Univ Melbourne, Australian Ovarian Canc Study, Peter MacCallum Canc Ctr, Dept Biochem, Melbourne, Vic 8006, Australia

[3] Ovarian Canc Act Res Ctr, London W12 0NN, England

[4] Royal Marsden Hosp, London SW3 6JJ, England

[5] Univ Texas MD Anderson Canc Ctr, Ovarian Canc Res Lab, Houston, TX 77030 USA

[6] Duke Univ, Med Ctr, Div Gynecol Oncol, Durham, NC 27710 USA

[7] Stanford Univ, Stanford Womens Canc Ctr, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA

[8] Canc Res UK, Li Ka Shing Ctr, Cambridge CB2 0RE, England

[9] Queen Mary Univ London, Ctr Canc & Inflammat, Barts & London Med Sch, London EC1M 6BQ, England

[10] Univ London Imperial Coll Sci Technol & Med, Div Immunol & Inflammat, London SW7 2AZ, England

[11] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77230 USA

[12] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77230 USA

[13] Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada

[14] Indiana Univ Sch Med, Bloomington, IN 47405 USA

[15] UCL, Elizabeth Garrett Inst Womens Hlth, London NW1 2BU, England

[16] Queen Mary Univ London, Barts Canc Inst, London EC1M 6BQ, England

[17] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[18] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[19] Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Inst, London SW3 6JB, England

[20] Royal Marsden Hosp, Inst Canc Res, Med Sect, Sutton SM2 5PT, Surrey, England

[21] Prince Wales Canc Ctr, Dept Med Oncol, Randwick, NSW 2031, Australia

[22] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia

[23] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA

[24] Univ Penn, Ctr Res Womens Hlth, Philadelphia, PA 19104 USA

[25] Brigham & Womens Hosp, Boston, MA 02445 USA

来源：

NATURE REVIEWS CANCER | 2011年 / 11卷 / 10期

基金：

英国医学研究理事会;

关键词：

LYMPHOCYTE-ASSOCIATED ANTIGEN-4; GRADE SEROUS CARCINOMA; REGULATORY T-CELLS; CLEAR-CELL; ANTIBODY BLOCKADE; GENOMIC ANALYSIS; TUMOR-CELLS; MOUSE MODEL; MUTATIONS; EVOLUTION;

D O I：

10.1038/nrc3144

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There have been major advances in our understanding of the cellular and molecular biology of the human malignancies that are collectively referred to as ovarian cancer. At a recent Helene Harris Memorial Trust meeting, an international group of researchers considered actions that should be taken to improve the outcome for women with ovarian cancer. Nine major recommendations are outlined in this Opinion article.

引用

页码：719 / 725

页数：7

共 87 条

[1] Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary [J].

Ahmed, Ashour Ahmed ;

Etemadmoghadam, Dariush ;

Temple, Jillian ;

Lynch, Andy G. ;

Riad, Mohamed ;

Sharma, Raghwa ;

Stewart, Colin ;

Fereday, Sian ;

Caldas, Carlos ;

DeFazio, Anna ;

Bowtell, David ;

Brenton, James D. .

JOURNAL OF PATHOLOGY, 2010, 221 (01) :49-56

[2] Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma [J].

Al-Barrak, J. ;

Santos, J. L. ;

Tinker, A. ;

Hoskins, P. ;

Gilks, C. B. ;

Lau, H. ;

Swenerton, K. D. .

GYNECOLOGIC ONCOLOGY, 2011, 122 (01) :107-110

[3] IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer [J].

Anglesio, Michael S. ;

George, Joshy ;

Kulbe, Hagen ;

Friedlander, Michael ;

Rischin, Danny ;

Lemech, Charlotte ;

Power, Jeremy ;

Coward, Jermaine ;

Cowin, Prue A. ;

House, Colin M. ;

Chakravarty, Probir ;

Gorringe, Kylie L. ;

Campbell, Ian G. ;

Okamoto, Aikou ;

Birrer, Michael J. ;

Huntsman, David G. ;

de Fazio, Anna ;

Kalloger, Steve E. ;

Balkwill, Frances ;

Gilks, C. Blake ;

Bowtell, David D. .

CLINICAL CANCER RESEARCH, 2011, 17 (08) :2538-2548

[4] Signal in noise: Evaluating reported reproducibility of serum proteomic tests for ovarian cancer [J].

Baggerly, KA ;

Morris, JS ;

Edmonson, SR ;

Coombes, KR .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (04) :307-309

[5] Cancer and Inflammation: Implications for Pharmacology and Therapeutics [J].

Balkwill, F. ;

Mantovani, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (04) :401-406

[6] Making the best of PARP inhibitors in ovarian cancer [J].

Banerjee, Susana ;

Kaye, Stan B. ;

Ashworth, Alan .

NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (09) :508-519

[7] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[8] Common variants at 19p13 are associated with susceptibility to ovarian cancer [J].

Bolton, Kelly L. ;

Tyrer, Jonathan ;

Song, Honglin ;

Ramus, Susan J. ;

Notaridou, Maria ;

Jones, Chris ;

Sher, Tanya ;

Gentry-Maharaj, Aleksandra ;

Wozniak, Eva ;

Tsai, Ya-Yu ;

Weidhaas, Joanne ;

Paik, Daniel ;

Van den Berg, David J. ;

Stram, Daniel O. ;

Pearce, Celeste Leigh ;

Wu, Anna H. ;

Brewster, Wendy ;

Anton-Culver, Hoda ;

Ziogas, Argyrios ;

Narod, Steven A. ;

Levine, Douglas A. ;

Kaye, Stanley B. ;

Brown, Robert ;

Paul, Jim ;

Flanagan, James ;

Sieh, Weiva ;

McGuire, Valerie ;

Whittemore, Alice S. ;

Campbell, Ian ;

Gore, Martin E. ;

Lissowska, Jolanta ;

Yang, Hanna P. ;

Medrek, Krzysztof ;

Gronwald, Jacek ;

Lubinski, Jan ;

Jakubowska, Anna ;

Le, Nhu D. ;

Cook, Linda S. ;

Kelemen, Linda E. ;

Brook-Wilson, Angela ;

Massuger, Leon F. A. G. ;

Kiemeney, Lambertus A. ;

Aben, Katja K. H. ;

van Altena, Anne M. ;

Houlston, Richard ;

Tomlinson, Ian ;

Palmieri, Rachel T. ;

Moorman, Patricia G. ;

Schildkraut, Joellen ;

Iversen, Edwin S. .

NATURE GENETICS, 2010, 42 (10) :880-+

[9] The genesis and evolution of high-grade serous ovarian cancer [J].

Bowtell, David D. L. .

NATURE REVIEWS CANCER, 2010, 10 (11) :803-808

[10] The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection [J].

Brown, Patrick O. ;

Palmer, Chana .

PLOS MEDICINE, 2009, 6 (07)

← 1 2 3 4 5 6 7 8 9 →